Tazarotene topical receptor-selective retinoid data

At an investment meeting in New York, the Irvine, Calif., company announced initial Phase III results in 324 patients with plaque psoriasis, saying that both 0.1 and 0.05 percent gels performed better than placebo, with an acceptable safety profile. FDA approval will be sought by mid-1995.

Patients were treated once daily for 12 weeks and then followed for an additional 12 weeks. On the trunk and limbs, 70 percent of patients treated with 0.1 percent concentration had good to complete clearing of lesions, with the 0.05 percent treatment giving 60 percent success; both values were statistically significant. ...